Camel-IDS NV - Company Review
Camel-IDS NV - Company ReviewSummary
Camel-IDS NV (Camel-IDS) is a biotechnology company which develops targeted radionuclide therapeutic solutions for the treatment of cancer. The company focuses on developing its lead compound radiopharmaceutical drug for treatment of Her2 positive cancer. Its technology platform is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (sdAbs) coupled with radioisotope to kill cancer cells. The company works in partnership with research institutions and organizations such as Vrije Universiteit Brussel (VUB), UZ Brussel, Fournier-Majoie Foundation, Biowin and VIB (Life Sciences Research Institute). Camel-IDS is headquartered in Brussels, Belgium.
This comprehensive company report of Camel-IDS NV provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.